Intas CEO expects to break into U.S. biosimilar market yet this year

The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's ($AMGN) Neulasta, a drug it developed with Canada's Apotex. That would make it the first of the Indian drugmakers that have been selling biosimilars in their native country to break into the U.S. market, Reuters points out. The U.S. biosimilar market is brand-new, with only Novartis' ($NVS) Zarxio, a copy of Amgen's Neupogen, approved and in the market. Story | More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.